Page 121 - CIBEREHD2016-ENG

• Immunotherapy with immunological checkpoint inhibitors and universal and personalized peptide vaccines.
• Improved procedures and materials for intra-arterial therapy of liver tumors: radioembolization and chemoembolization .
• Improvement of the procedures and results of the surgical treatment of liver cancer including liver
Most relevant scientific articles
• D’Avola D., Lopez-Franco E., Sangro B., Paneda A., Grossios N., Gil-Farina I. et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. Journal of Hepatology. 2016.
• de la Torre M.A., Buades-Mateu J., de la Rosa P.A., Lue A., Bustamante F.J., Serrano M.T. et al. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver International. 2016.
• Urtasun R., Elizalde M., Azkona M., Latasa M.U., Garcia-Irigoyen O., Uriarte I. et al. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17- 92 cluster expression. Oncogene. 2016;35(36):4719-4729.
• Forner A., Reig M., Varela M., Burrel M., Feliu J., Briceno J. et al. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Medicina Clinica. 2016.
• Bigaud E., Corrales F.J.. Methylthioadenosine (MTA) regulates liver cells proteome and methylproteome: Implications in liver biology and disease. Molecular and Cellular Proteomics. 2016;15(5):1498-1510.
Hightlights
The research activity of the group has remained intense in all fields. Competitive funding has been obtained from national agencies and the European Commission, and collaborations with foreign and national groups have been strengthened, both within and outside CIBEREHD. We continue to work on mechanisms of carcinogenesis, elucidating the role of molecules such as SLU7 or YAP1 and their epigenetic regulation, a research line on the role of lncRNA has been opened, and work has begun on a tool to predict response to treatment in hepatocellular carcinoma with targeted molecules. Based on the strategic action granted, collaborative studies of molecular classification of cholangiocarcinoma and identification of therapeutic targets are being carried out. In immunology and immunotherapy of hepatocellular carcinoma, we collaborate in the identification of the possible immunological mechanism of induction of relapse after treatment with direct acting antivirals in patients with hepatocellular carcinoma, we will communicate the final results of clinical trials with immune checkpoints inhibitors, we will begin the recruitment of a clinical trial using a multi-peptide vaccine, and we have organized early trials of combinations of these molecules with other agents, seeking therapeutic synergies. The collaboration with engineers for the development of computational fluid dynamics systems for the improvement of intra-arterial treatments is still active. The results of the first clinical trial of the treatment of acute intermittent porphyria have been reported and progress is being made in the development of an improved gene transfer system, which is intended to lead to clinical experimentation in the near future. Collaborative studies aim at improving the results of liver transplantation, especially in patients with liver cancer. Finally, we have collaborated in the update of the Spanish Guidelines for the Treatment of Hepatocellular Carcinoma, which will be part of the portfolio of Clinical Practice Guidelines of the Ministry of Health.
EHD
research Groups 121